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TECHNICAL NOTE / Oncology
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Pain  management  of  bone  metastases  is  usually  made  using  systemic  and  local  therapy.
Even  though  radiations  are  nowadays  the  gold  standard  for  painful  metastases,  innova-
tions  regarding  minimally  invasive  treatment  approaches  have  been  developed  because
of  the  existing  non-responder  patients  [1]. Indeed,  cementoplasty  and  thermo-ablations
like  radiofrequency  or  cryotherapy  have  shown  to  be  efﬁcient  on  pain  [2—4].  Among  ther-
motherapy,  magnetic  resonance  guided  focalised  ultrasound  is  now  a  new  non-invasive
weapon  for  bone  pain  palliation.
Discussion
Magnetic  resonance  image-guided  focused  ultrasound  surgery  (MRgFUS,  ExAblate,
InSightec,  Tirat  Carmel,  Israel)  is  an  innovative  technology  combining  two  distinct
approaches:  high-intensity  focused  ultrasound  (HIFU)  and  a  magnetic  resonance  imaging
system  (MRI)  [5].
HIFU  is  a  well-known  technique,  which  has  been  ﬁrst  introduced  for  biological  abla-
tion  in  1942  [6].  It  allows  destroying  targeted  tissue  not  invasively  by  increasing  the
temperature  locally.  What  is  new  about  it  is  the  MRI  guidance  and  monitoring.  Indeed,
functional  and  morphologic  sequences  provide  both  accurate  localisation  targeted  tumours
and  temperature  monitoring  [7—9].
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results  are  very  promising  and  a larger  multicenter  study40  
The  device  is  made  of  a  modiﬁed  table  compatible  with
he  existing  MRI  platform  and  a  workstation  to  control  the
ystem  (Fig.  1).
Focused  ultrasound  waves  are  generated  from  a  phased
rray  transducer  with  256  elements.  The  waves  are  focused
or  15  to  25  seconds  to  yield  heat  on  an  ellipsoid-shaped  spot
easuring  up  to  7  cm.  Each  ultrasound  energy  deposition  is
alled  ‘‘sonication’’.
The  energy  delivered  by  a  single  shoot  is  sufﬁcient  to
ncrease  tissue  temperature  above  the  denaturing  proteins
hermal  dose  threshold.  It  results  in  a  coagulative  necrosis
10].
The  operator  desktop  station  allows  both  the  MRI  and
he  HIFU  system  control.  After  calibration,  the  ﬁrst  step  is
he  deﬁnition  of  the  treatment  zone.  T2-weighted  images
re  used  by  the  physician  to  deﬁne  the  tumor  target.  More-
ver,  the  fusion  with  CT  scan  can  be  helpful.  Then,  to  ensure
hat  the  entire  volume  receives  adequate  thermal  dose,  the
oftware  proposes  a  three  dimension  treatment  plan  com-
osed  of  multiple  sonications  [10,11].  However,  the  operator
an  change  the  shape,  size,  intensity  of  the  acoustic  beams
o  tailor  the  treatment  ‘‘in  real  time’’  and  protect  sur-
ounding  organs  at  risk  [12,13].  On  the  screen,  feedback
o  predict  efﬁciency  of  the  sonication  is  available  through
ltrasound  propagation  monitoring  and  in  vivo  magnetic  res-
nance  thermal  map  (Fig.  2)  [14].  In  addition,  after  the
rocedure,  a  post-contrast  sequence  offers  an  estimation  of
he  ablated  tissue  which  turns  out  to  be  non-perfused.  Also,
unctional  MRI  sequences  could  improve  residual  tumour
stimation  after  treatment  using  perfusion  MR  or  diffusion
eighted  imaging.
igure 1. Painful rib metastasis treated by MRgFUS, hardware device a
eft thoracic pain (numerical scale = 6/10). A whole body PET-CT has be
xial T2-weighted MR is performed to be sure that the targeted rib lesion
erformed on the periosteum (hypersignal T2) allows pain control (plain
atient has to be installed in ventral decubitus position to expose the 
ontact with the gel pad and the water bath (star) to avoid air interfac
o a water source (plain arrowhead).
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For  bones,  the  targeted  ablation  aims  at  denervating  the
eriostium  invaded  by  the  tumour  and  yielding  pain  relief.  In
his  case,  the  focus  point  is  placed  behind  the  targeted  bone
o  allow  a  larger  ﬁeld  of  heating  (Fig.  2).  This  is  made  possi-
le  because  bone  absorbs  about  50  times  as  much  ultrasound
nergy  as  soft  tissues  [15].
Typical  bone  procedure  lasts  2  hours,  including  approx-
mately  1  h  of  sonication  time.  As  the  periosteal  ablation
s  painful,  the  anaesthesia  management  is  a  key  factor  to
aintain  the  patient’s  comfort,  avoids  movements  during
he  procedure,  and  allows  the  physician  to  reach  adequate
evels  of  energy.  Two  options  are  possible:  ﬁrst,  a  locore-
ional  anaesthesia  like  nerve  block  or  spinal;  second,  the
ombination  of  a  deep  sedation  and  a  local  anaesthesia  (usu-
lly  performed  under  x-ray  guidance).
MRgFUS  device  is  approved  by  Food  and  Drug  Admin-
stration  (FDA)  and  the  European  Community  (CE)  for  the
reatment  of  uterine  ﬁbroma  and  painful  bone  metastases
nd  is  currently  under  evaluation  for  the  treatment  of  solid
umours  in  the  brain,  breast,  prostate,  liver  and  pancreas
16—19].  Others  devices  are  available  but  only  two  are
uided  by  MRI.  Each  system  needs  to  be  marked  for  a  spe-
iﬁc  indication;  we  have  summarised  the  existing  devices  in
able  1.
Among  different  studies,  all  patients  have  reported  fast
<  48  h)  and  signiﬁcant  pain  reduction  (Visual  score  drop  >  2
oints)  in  treated  bones  and  a  drop  in  the  use  of  painkillers
19,20].  No  adverse  events  have  been  recorded.  Thesend patient positioning. A 54-year-old patient with lung cancer has
en performed and showed a left rib lesion. Before treatment, an
 is visible (empty arrow). During the treatment, a local anaesthesia
 arrow). As the transducer (red prism) is inside the MRI table, the
target toward the ultrasound beam. The skin must be directly in
e (risk of skin burn). The system needs a cooler system connected
or  bone  palliation  using  the  MRgFUS  approach  is  being  con-
ucted  to  compare  it  with  radiation.  The  real  challenge
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Figure 2. Painful rib metastasis treated by MRgFUS, during the treatment. Same patient in Fig. 1. The system allows both control and
veriﬁcation during the procedure. The thermal map sequence is repeated each 4 seconds for 30 seconds (empty arrowhead). The morphologic
T2-weighted images are required to detect movements (plain cross). For bone, the cortical surface (green line) is the target of the lesion
and beam focalisation is voluntary planned behind it. The yellow circle represents the area of heating for one sonication. All parameters
are accessible and can be modiﬁed (empty star). The sonication time is 20 seconds and the thermal curve shows the correct increase and
tient
e
r
tdecrease of the temperature (empty cross). After treatment, the pa
lasting 6 months after the procedure.
for  oncology  is  to  treat  malignant  lesions  with  a  curative
endpoint  as  an  alternative  to  surgical  resection.  We  think
that  the  best  research  ﬁelds  are  expected  for  localised  can-
cer,  precancerous  lesions  or  as  a  second  option  after  an
initial  surgery  [21,22].  Curative  approach  has  been
Table  1  High  intensity  focalised  ultrasound  devices
available  for  medical  use.
Company  Commercial  name  Guidance
InSightec,  Haifa,  Israel  ExAblate  2000
ExAblate  4000
MR
Philips  Healthcare,
Netherlands
Sonalleve  MR-HIFU
Chongqing  Haifu,  China  Haifu  US
Misonix,  US  Sonablate  500
EDAP,  France  Ablatherm  HIFU
Theraclion,  France  TH-One
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c was completely relieved within 48 hours and the pain relief is still
valuated  for  breast  cancer  by  some  promising  studies  and
equires  a  larger  study  with  a  perfect  design  (i.e.  conﬁrma-
ion  lumpectomy)  [23—26]. Actually,  thanks  to  new  higher
nergy  and  multi-element  transducers  experimental  brain
pplications  are  very  promising  without  craniotomy  [27,28].
n  fact,  FDA  approval  has  been  obtained  for  treatment  of
ssential  tremor.
Prostate  is  commonly  treated  with  surgery,  radiothe-
apy,  cryotherapy  and  HIFU  guided  by  ultrasound.  Speciﬁc
ntrarectal  transducers  are  available  to  treat  prostatic  can-
er  [29,30]. Abdomen  applications  are  being  investigated  to
olve  movement  problems  [31—36].
The  pros  and  cons  of  MR  guided  ultrasound  thermo-
blation  compared  to  other  local  approaches  such  as  surgery
nd  radiotherapy  are  shown  in  Table  2. For  curative  project,
on-invasive  approach  is  usually  a  second  line  therapy  due
o  the  absence  of  pathological  conﬁrmation.  However,  a
reatment  combining  ultrasound  thermo-ablation  for  the
argeted  macroscopic  solid  tumours  with  radiotherapy  for
ub-microscopic  sterilization  might  be  a  future  strategy  to
onsider  [37].
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Table  2  Advantages  and  disadvantages  of  local  treatments  for  cancer.
MRgFUS  Surgery  Radiation
Destroying  medium
Non  invasive  =  Heat  Invasive  technique  =  Lancet
higher  morbidity  risk  (blood  loss)
Non  invasive  =  ionizing  radiation
Anaesthesia
Local  or  deep  sedation  Deep  sedation  or  general  anaesthesia  Not  required
Initial  evaluation  (completeness  of
treatment)
Macroscopic  disease:  gadolinium
MRI,  functionnal  MRI
(DWI-Perfusion)
Macroscopic  and  microscopic  disease:
pathological  conﬁrmation  (enables
chemotherapy  adaptation)
Macroscopic  and  microscopic  disease:
not  evaluable
Microscopic  and  submicroscopic
disease:  undetectable
Submicroscopic  disease:  undetectable  Submicroscopic  disease:  theoretical
sterilization  (adjuvant  treatment)
Time  and  cost  evaluation
Single  procedure  Single  procedure  Multiple  procedure
Short  procedure  Long  procedure  Short  procedure
Short  hospitalization  Follow-up  hospitalization  No  hospitalization
MRI  required
Treatment  limitations
Ultrasound  penetration Resectability Dose  limitation
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[limitation Patient  comorbidity
onclusion
R  guided  ultrasound  thermo-ablation  is  a  promising  non-
nvasive  technique  offering  new  opportunities  for  the
reatment  of  cancer  patients.  However,  its  efﬁcacy  in  the
reatment  of  solid  cancer  has  still  to  be  proved  by  larger
rials  alone  or  combined  with  surgery  or  radiations.
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